Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer.
作者信息
Bartoletti Michele, Pignata Sandro, Lorusso Domenica, Perrone Francesco, Zara Diego, Puglisi Fabio
机构信息
Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy.
Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
出版信息
JAMA Netw Open. 2022 Dec 1;5(12):e2245077. doi: 10.1001/jamanetworkopen.2022.45077.
Abstract
摘要
相似文献
1
Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer.晚期卵巢癌靶向治疗试验中的需治疗人数
JAMA Netw Open. 2022 Dec 1;5(12):e2245077. doi: 10.1001/jamanetworkopen.2022.45077.
2
Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer.晚期上皮性卵巢癌系统治疗相关影像学表现概述。
Abdom Radiol (NY). 2020 Mar;45(3):828-841. doi: 10.1007/s00261-019-02175-0.
3
PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis.聚腺苷二磷酸核糖聚合酶抑制剂作为新诊断的晚期卵巢癌的维持治疗：一项荟萃分析。
BJOG. 2021 Feb;128(3):485-493. doi: 10.1111/1471-0528.16411. Epub 2020 Aug 2.
4
Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.上皮性卵巢癌的维持治疗：从化疗到靶向药物
Expert Rev Anticancer Ther. 2014 Sep;14(9):1041-50. doi: 10.1586/14737140.2014.922415. Epub 2014 Jun 23.
5
Ovarian cancer and the immune system - The role of targeted therapies.卵巢癌与免疫系统——靶向治疗的作用
Gynecol Oncol. 2016 Aug;142(2):349-56. doi: 10.1016/j.ygyno.2016.05.007. Epub 2016 May 23.
6
Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.卵巢癌新型靶向治疗的临床试验：超越聚腺苷酸二磷酸核糖聚合酶（PARP）抑制剂
Curr Pharm Biotechnol. 2018;19(14):1114-1121. doi: 10.2174/1389201020666181226123054.
7
[IV. Targeted therapies for epithelial ovarian cancer].
Gan To Kagaku Ryoho. 2014 Feb;41(2):193-8.
8
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.PARP抑制剂与抗血管生成治疗联合用于晚期上皮性卵巢癌的理论依据：综述
Gynecol Oncol. 2021 Aug;162(2):482-495. doi: 10.1016/j.ygyno.2021.05.018. Epub 2021 Jun 3.
9
Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.贝伐珠单抗作为新诊断的上皮癌的一线治疗。
Expert Rev Anticancer Ther. 2013 Feb;13(2):123-9. doi: 10.1586/era.12.165.
10
Clinical trials and future potential of targeted therapy for ovarian cancer.卵巢癌靶向治疗的临床试验和未来潜力。
Int J Clin Oncol. 2012 Oct;17(5):430-40. doi: 10.1007/s10147-012-0459-8. Epub 2012 Aug 28.
引用本文的文献
1
Proportion of patients in phase 2 oncology trials receiving treatments that are ultimately approved.在2期肿瘤学试验中接受最终获批治疗的患者比例。
J Natl Cancer Inst. 2025 May 1;117(5):1056-1063. doi: 10.1093/jnci/djaf013.
2
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial.通过结合基因组和功能方法揭示卵巢癌中HRD评估的复杂性：MITO16-MaNGO-OV-2试验的转化分析
ESMO Open. 2025 Jan;10(1):104091. doi: 10.1016/j.esmoop.2024.104091. Epub 2025 Jan 3.
3
Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer.基于拓扑替康或拓扑替康与环磷酰胺联合方案（CyTo）的节拍化疗在晚期、经治卵巢癌中的应用
Cancers (Basel). 2023 Feb 7;15(4):1067. doi: 10.3390/cancers15041067.
本文引用的文献
1
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).一项评价芦卡帕利单药作为新诊断卵巢癌患者维持治疗的随机、III 期临床试验（ATHENA-MONO/GOG-3020/ENGOT-ov45）。
J Clin Oncol. 2022 Dec 1;40(34):3952-3964. doi: 10.1200/JCO.22.01003. Epub 2022 Jun 6.
2
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.奥拉帕利维持治疗新诊断的 BRCA 突变晚期卵巢癌患者（SOLO1/GOG 3004）：一项随机、双盲、安慰剂对照、III 期临床试验的 5 年随访。
Lancet Oncol. 2021 Dec;22(12):1721-1731. doi: 10.1016/S1470-2045(21)00531-3. Epub 2021 Oct 26.
3
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.一线治疗卵巢癌中无进展生存期作为总生存期替代终点的评估：系统评价和荟萃分析。
JAMA Netw Open. 2020 Jan 3;3(1):e1918939. doi: 10.1001/jamanetworkopen.2019.18939.
4
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.奥拉帕利联合贝伐珠单抗作为卵巢癌一线维持治疗。
N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.
5
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.尼拉帕利治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
6
A phase 3 trial of bevacizumab in ovarian cancer.贝伐珠单抗治疗卵巢癌的 III 期临床试验。
N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799.
Zotero 插件